Race Oncology (ASX: RAC) raises $29.7m to fund development of lead anti-cancer drug Zantrene (w/ Daniel Tillett)

Race Oncology (ASX: RAC) chief scientific officer Dr Daniel Tillett joins Small Caps to discuss the company’s research and development plans for its lead anti-cancer drug Zantrene. As well as having an anti-cancer effect, recent pre-clinical research has also identified the drug has heart-protective benefits. Race is heading into 2022 with an extra $29.7 million after it completed a heavily oversubscribed share purchase plan.Articles: https://smallcaps.com.au/race-oncology-2022-extra-bank-advance-lead-drug-zantrene/https://smallcaps.com.au/race-oncology-zantrene-heart-protective-research-university-of-newcastle/https://smallcaps.com.au/race-oncology-drug-zantrene-cardio-protective-properties-during-cancer-treatment/More company information:https://smallcaps.com.au/stocks/RAC/See omnystudio.com/listener for privacy information.